TORRANCE, Calif.--(BUSINESS WIRE)--Celprogen Inc., a leader in the Stem Cell Research and Therapeutics industry for the development of stem cell technologies for regenerative medicine, today announced that they have developed a novel pharmacological Inhibitor CEP1430 synthetic molecule that is capable of inhibiting the growth and proliferation of the human pancreatic cancer tumor. This molecule can be administrated by the following methods: intravenous and intra-peritoneal. The molecule CEP1430 will be presented at the American Association for Cancer Research Annual Meeting in Philadelphia, Tuesday, April 21, 2015, 1:00 PM - 5:00 PM; Therapeutics Targeting Cancer Stem Cells.
Help employers find you! Check out all the jobs and post your resume.
